Free Trial

Avidity Biosciences (RNA) Stock Forecast & Price Target

Avidity Biosciences logo
$31.64 -0.18 (-0.57%)
(As of 05:45 PM ET)

Avidity Biosciences - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
11

Based on 11 Wall Street analysts who have issued ratings for Avidity Biosciences in the last 12 months, the stock has a consensus rating of "Buy." Out of the 11 analysts, 11 have given a buy rating for RNA.

Consensus Price Target

$64.36
103.42% Upside
According to the 11 analysts' twelve-month price targets for Avidity Biosciences, the average price target is $64.36. The highest price target for RNA is $96.00, while the lowest price target for RNA is $45.00. The average price target represents a forecasted upside of 103.42% from the current price of $31.64.
Get the Latest News and Ratings for RNA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Avidity Biosciences and its competitors.

Sign Up

RNA Analyst Ratings Over Time

TypeCurrent Forecast
12/24/23 to 12/23/24
1 Month Ago
11/24/23 to 11/23/24
3 Months Ago
9/25/23 to 9/24/24
1 Year Ago
12/24/22 to 12/24/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
11 Buy rating(s)
9 Buy rating(s)
8 Buy rating(s)
5 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$64.36$63.22$60.75$31.60
Forecasted Upside103.42% Upside46.18% Upside38.07% Upside242.92% Upside
Consensus Rating
Buy
Buy
Buy
Buy

RNA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RNA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Avidity Biosciences Stock vs. The Competition

TypeAvidity BiosciencesMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.81
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside103.42% Upside26,151.52% Upside14.41% Upside
News Sentiment Rating
Neutral News

See Recent RNA News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/20/2024HC Wainwright
2 of 5 stars
A. Ghosh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$72.00+131.88%
11/26/2024Royal Bank of Canada
4 of 5 stars
L. Issi
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$67.00+48.46%
11/13/2024Chardan Capital
1 of 5 stars
K. Nakae
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$65.00 ➝ $65.00+23.81%
11/13/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$60.00 ➝ $60.00+28.40%
10/21/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$56.00 ➝ $78.00+68.69%
9/24/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Johnson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$59.00+35.63%
9/16/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Schmidt
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$96.00 ➝ $96.00+132.11%
8/28/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
G. Wang
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$63.00+44.10%
8/26/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
G. Clark-Gartner
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$54.00 ➝ $53.00+21.12%
6/13/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$40.00 ➝ $45.00+13.18%
1/3/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$50.00+422.47%
8/9/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$30.00+220.86%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 07:31 PM ET.


RNA Forecast - Frequently Asked Questions

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Avidity Biosciences is $64.36, with a high forecast of $96.00 and a low forecast of $45.00.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avidity Biosciences in the last year. There are currently 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RNA shares.

According to analysts, Avidity Biosciences's stock has a predicted upside of 103.42% based on their 12-month stock forecasts.

Avidity Biosciences has been rated by research analysts at Chardan Capital, HC Wainwright, Needham & Company LLC, Royal Bank of Canada, TD Cowen, and The Goldman Sachs Group in the past 90 days.

Analysts like Avidity Biosciences more than other "medical" companies. The consensus rating for Avidity Biosciences is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how RNA compares to other companies.


This page (NASDAQ:RNA) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners